Formosa Pharmaceuticals, Inc

Formosa Pharmaceuticals () is a clinical stage biopharmaceutical company with primary focus in ophthalmology and oncology. Our flagship asset, APP13007 (Clobetasol Propionate ophthalmic suspension 0.05%) was recently approved by the US FDA (March, 2024) for the treatment of post-operative inflammation and pain following ocular surgery. In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan. With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platforms scope and application. APNT effectively reduces API particle size to improve...

Formosa pharmaceuticals, inc operates in the Pharmaceutical manufacturing industry.

Formosa pharmaceuticals, inc's revenue is 11m - 100m

Formosa pharmaceuticals, inc has 11 - 50 employees.